Quarterly Report • Oct 25, 2011
Quarterly Report
Open in ViewerOpens in native device viewer
(Figures in brackets refer to the same period of last year)
"We are extremely pleased to note continued excellent growth in sales for both of our product segments. Due to the summer holiday in Europe, the third quarter is normally our weakest period in terms of sales. Thanks to a few substantial orders from Nestlé, however, the third quarter was unusually strong." says Peter Rothschild, President of BioGaia.
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 25 October 2011, 8:00 a.m. CET.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
The Board of Directors and the President of BioGaia AB (publ) hereby present the interim report for the period from 1 January to 30 September 2011. A brief description of the company's operations is provided on page 13.
We are extremely pleased to note continued excellent growth in sales for both of our product segments.
Due to the summer holiday in Europe, the third quarter is normally our weakest period in terms of sales. Thanks to a few substantial orders from Nestlé, however, the third quarter was unusually strong. It is very positive that Nestlé has made such a good start and is continuing its launches in a number of countries. Since we give Nestlé contractual volume discounts, this will impact our margins during the second half of this year. The large volumes will give us scale economies and thereby opportunities to reduce our costs for culture production. In spite of these discounts, our operating margin for the first three quarters of 2011 is a very solid 34%.
It is satisfying to see sustained and strong sales growth also for our finished consumer products, and that applies to all of our different products, tablets, drops, the oral health product and the oral rehydration product. The drops sold to colicky infants is our top-selling product and is still showing rapid growth.
Sales development in Japan remains positive and we hope that our activities there will be profitable in the near future. Since we primarily sell oral health products in Japan, this product group has also increased.
Our sales in the USA are still unacceptably low, but our focus on this market is starting to pay off. In this regard I am referring not only to our new agreement with Fleet, who will launch the strawberry-flavoured tablets at the beginning of next year, but also the fact that our distributor Everidis has introduced our new version of room temperature storage drops in a large number of Walgreens sales outlets. Walgreens is the USA's largest drug store chain with a total of more than 7,000 stores.
Consolidated net sales reached SEK 232.6 million (173.3), an increase of 34% compared to the same period of last year.
Most of the company's sales are denominated in foreign currency, mainly EUR. With unchanged exchange rates, net sales would have been SEK 14.7 million higher. Excluding foreign exchange effects, the increase in net sales would have been 43%. Exchange rate fluctuations have reduced both income and expenses. Operating profit would have been SEK 9.3 million higher in the event of unchanged exchange rates.
Sales increased in both segments (finished consumer products and component products) and in all markets except for North America.
Sales of finished consumer products rose by SEK 37.0 million (31%) to SEK 158 million. The increase referred to all markets, but primarily Europe and Asia. Sales of component products were up by SEK 22.4 million (44%) to SEK 73.2 million, which is mainly attributable to sales of bacteria cultures to Nestlé.
Sales in Asia grew by SEK 14.3 million (94%) from SEK 15.2 million to SEK 29.5 million. This is mainly due to higher sales in Japan but also to the fact that negotiations with Yili in China led to a solution that contributed to higher sales during the period. The increase in Asia referred primarily to finished consumer products.
Sales in Europe rose by SEK 42.7 million to SEK 173.8 million (33%), which is mainly explained by sales of bacteria cultures to Nestlé as well as increased sales of finished consumer products above all in Italy and Eastern Europe. Final sales of Nestlé's products also take place outside Europe. However, in the future Nestlé may produce the culture itself and BioGaia will in such a case receive royalties from Nestlé instead of income from culture deliveries. This would lead to lower sales and a somewhat lower gross profit, but a higher gross margin than today.
Sales in the USA and Canada fell from SEK 11.7 million to SEK 9.3 million (-21%), mainly due to Nestlé's discontinued sales of beverages with BioGaia's LifeTop Straw.
Sales in the rest of the world rose from SEK 15.4 million to SEK 20.0 million (30%) as a result of higher sales of finished consumer products in Australia and South America.
Of total finished consumer products, 42% (37) were sold under the BioGaia brand.
Gross profit amounted to SEK 159.0 million (115.5), an improvement of SEK 43.5 million compared to the same period of last year. Gross margin rose from 67% to 68%, mainly because the consolidation of TwoPac in 2011 has reduced the group's cost of goods sold. For more information, see page 8. Gross margin fell somewhat in the third quarter as a result of contractual volume discounts to Nestlé.
Selling expenses were up by SEK 2.8 million compared to the same period of last year. Selling expenses for the corresponding period of 2010 included one-time costs of around SEK 4.0 million. Aside from these, selling expenses rose by SEK 6.8 million primarily as an effect of increased marketing activities and higher personnel expenses.
Administrative expenses increased by SEK 2.0 million, mainly owing to the fact that administrative expenses in TwoPac AB, which is now reported as a group company, were not included in the same period of last year.
R&D expenses amounted to SEK 24.4 million (22.1), which is equal to 16% (16) of total operating expenses and 11% (13) of net sales. The increase of SEK 2.3 million is explained by higher activity in product development and clinical trials.
The amortisation component of R&D expenses was SEK 1.0 million (1.1). Investments in capitalised development expenses totalled SEK 0 million (0).
Other operating income/expenses refer to foreign exchange gains/losses on operating receivables and liabilities. For the period from January to September
2011 these gave rise to operating income of SEK 1.5 million, compared to an operating expense of SEK 2.7 million in the same period of last year.
Operating profit was SEK 79.4 million (40.1), which is SEK 39.3 million (98%) better than in the same period of last year. Excluding foreign exchange effects (see above under "Sales"), operating profit improved by 121%.
Profit before tax was SEK 79.2 million (51.1), an improvement of SEK 28.1 million (55%) over the same period of last year. Net financial items include a foreign exchange loss of SEK 2.2 million on forward exchange contracts in EUR (the same period of last year included a foreign exchange gain of SEK 10.5 million).
At 30 September 2011 the company had outstanding forward exchange contracts for EUR 14.5 million at an average exchange rate of SEK 9.34. Forward exchange contracts amounting to EUR 2.7 million will mature for payment in 2011, EUR 8.6 million in 2012 and the remaining SEK 3.2 million in 2013. The actual exchange gain/loss depends on the exchange rate on the maturity date of the contracts. If the EUR rate on the maturity date is lower/higher than that at 30 September 2011 (9.23), an exchange gain/loss will be recognised in the future.
Profit after tax was SEK 57.8 million (34.3), which represents an increase of SEK 23.5 million (69%) over the same period of last year.
The tax rate for the Group was 27% (33). The Group pays tax on profits in the Swedish companies. The loss in Japan is not deductible against the Swedish profits. Since the loss in Japan has decreased compared to the same period of last year, the tax rate for the Group is lower. Loss carryforwards in the Japanese subsidiary amount to SEK 51.4 million. The deferred tax asset for these has not been recognised, since a sustainable profit level has not yet been shown in the Japanese subsidiary.
Earnings per share amounted to SEK 3.24 (1.99).
The Group's cash and cash equivalents at 30 September 2011 totalled SEK 161.4 million (125.7).
Cash flow amounted to SEK 14.2 million (25.7), down by SEK 11.5 million compared to the same period of last year. This is partly due to payment of SEK 34.5 million (25.8) in dividends and partly due to payment of SEK 30.1 million in tax (of which SEK 18.4 million refers to the financial year 2010) during the period. In addition, investments in property, plant and equipment amounted to SEK 11.0 million (0.4), of which SEK 10.8 million refers to TwoPac.
Consolidated equity amounted to SEK 208.6 million (174.3) and the equity/assets ratio was 83% (82).
Investments in property, plant and equipment totalled SEK 11.0 million (0.4), of which SEK 10.8 million refers to TwoPac AB.
Until 31 December 2010, BioGaia's 50%-owned company TwoPac AB was reported as an associated company. As a result of BioGaia's decision to finance TwoPac's new factory in Eslöv (for more information see below), BioGaia has gained a controlling influence over TwoPac, which is thus consolidated as of 1 January 2011. Comparative figures for the corresponding period of last year are provided on page 8.
Net sales in the Parent Company were reported at SEK 225.6 million (173.3) and profit before tax was SEK 75.6 million (52.0). Due to uncertainty about whether the receivable from BioGaia Japan will be recovered in the foreseeable future, a provision has been made for this amount. This has led to an impairment loss of SEK 7.5 million (13.3) that has had a negative impact on earnings. Profit after tax was SEK 54.2 million (36.2). Cash flow in the Parent Company was SEK 8.4 million (26.4). Cash flow from investing activities includes a loan of SEK 3.6 million (11.2) to the Japanese subsidiary and a loan of SEK 11.1 million (0) to the subsidiary TwoPac.
Net sales for the third quarter reached SEK 73.1 million (48.9), up by SEK 24.2 million (49%) over the same period of last year. Excluding foreign exchange effects (see above under "Financial performance during the period from 1 January to 30 September 2011"), net sales rose by 53%.
Sales increased in all markets but primarily in Europe. Sale of finished consumer products grew by SEK 15.4 million (50%). Sales of component products improved by SEK 8.5 million (49%), which is mainly due to large deliveries of bacteria cultures to Nestlé.
Compared to the second quarter, net sales fell by SEK 16.5 million (18%). Third quarter sales are typically the lowest of the year due to the customary summer holiday in Europe, which results in a lower level of activity among BioGaia's customers and suppliers. However, the third quarter of 2011 was better than the first quarter, mainly due to large deliveries to Nestlé.
For a more accurate picture, a rolling 12-month income statement is presented on page 6.
Gross profit was SEK 47.8 million (32.1), an improvement of SEK 15.7 million over the same period of last year. Gross margin was 65%, which is lower than in the preceding quarter as a result of contractual volume discounts to Nestlé.
Selling expenses for the third quarter were SEK 1.3 million higher than in the same period of last year. The corresponding period of 2010 included one-time costs of around SEK 1.0 million attributable to expenses in Japan. Excluding these, selling expenses rose by SEK 2.3 million compared to the same period of last year, mainly as a result of increased marketing activities.
Administrative expenses increased by SEK 0.8 million compared to the same period of last year, mainly owing to the fact that administrative expenses in TwoPac AB, which is now reported as a group company, were not included in the same period of 2010.
R&D expenses rose by SEK 0.6 million compared to the same period of last year due to increased activity in product development and clinical trials.
Selling, administrative and R&D expenses were down compared to the preceding quarter as a result of lower activity during the customary summer holiday in Sweden and the rest of Europe.
Operating profit for the third quarter was SEK 22.1 million (8.6), an improvement of SEK 13.5 million (157%) over the same period of last year. Excluding foreign exchange effects (see above), the increase would have been 160%. Compared to the second quarter, operating profit was SEK 11.8 million lower.
Profit before tax for the third quarter was SEK 21.4 million (12.9), up by SEK 8.5 million (66%) compared to the same period of last year. Net financial items include a foreign exchange loss of SEK 1.5 million on forward exchange contracts in EUR (for more information – see above). The corresponding period of 2010 included a foreign exchange gain of SEK 3.9 million.
Profit after tax was SEK 15.6 (8.0) million, which is an improvement of SEK 7.6 million (95%) over the same period of last year.
Compared to the preceding quarter, profit after tax declined by SEK 8.1 million.
Cash flow from operating activities before changes in working capital was SEK 18.3 million (9.4).
Total cash flow for the third quarter was SEK 34.4 million (16.5).
| Distributor/licensee | Product | Country |
|---|---|---|
| Infant formula with | ||
| Nestlé | Reuteri | Algeria and Pakistan |
| Tablets with strawberry | ||
| flavour, | ||
| Semper | Drops with Vitamin D | Sweden |
At the beginning of August BioGaia signed an agreement with the Moroccan pharmaceutical company Galenica SA. The agreement gives Galenica exclusive rights to distribute BioGaia's Probiotic drops and tablets under the BioGaia brand in Morocco. The launch is planned for the first quarter of 2012.
In August BioGaia signed an agreement with Fleet Laboratories for the exclusive right to sell BioGaia's Probiotic chewable tablets with strawberry flavour in the USA and its territories (excluding Puerto Rico). Fleet will sell the Probiotic chewable tablets under its Pedia-Lax brand. The launch is planned for the first quarter of 2012.
In September BioGaia signed a distribution agreement with United Laboratories Incorporated, the largest pharmaceutical company in the Philippines, for its Probiotic chewable tablets. The tablets will be sold under the BioGaia brand and the launch is scheduled for the first half of 2012.
In October BioGaia signed a new agreement with Victus for the sale of BioGaia's Probiotic tablets and drops in Venezuela and Puerto Rico. The launches are expected to take place in 2012. Since 2001 Victus has purchased Lactobacillus reuteri Protectis for use in its product Glutapak-R.
| Distributor/licensee | Product | Country |
|---|---|---|
| Australia and New | ||
| Blackmores | Relaunch of tablets | Zealand |
| Oral Rehydration | ||
| Delta Medical | Solution (ORS) | Ukraine |
| Ewopharma | Oral health product | Slovakia and Bulgaria |
| Ferring | Tablets and drops | Guatemala |
| Ferring | Tablets (new flavour) | Greece |
| Laboratorios Casen | ||
| Fleet | Tablets (new flavour) | Spain |
| Infant formula with | Philippines, Iran, | |
| Nestlé | Reuteri | Indonesia and Malaysia |
| Oral Rehydration | ||
| Solution (ORS) and | ||
| Verman | drops with Vitamin D | Finland |
At the beginning of 2011 BioGaia signed an agreement with Cube Pharmaceuticals for exclusive rights to distribute BioGaia's new Oral Rehydration Solution (ORS) in Greece. The launch has been postponed and is now planned for the fourth quarter of 2011.
TwoPac, which is owned 50% by BioGaia and 50% by TwoPac's management, produces straws and oil drops containing probiotics as well as LifeTop Cap, a bottle cap which contains sensitive ingredients, for BioGaia. Due to growing volumes and stricter quality requirements from the authorities and customers, the existing facilities are no longer suitable and TwoPac has decided to build its own factory in Eslöv where the company currently rents premises.
The investment is estimated at approximately SEK 20 million and will be financed with TwoPac's own operating surplus and through a loan from BioGaia. The factory is expected to go into operation at the beginning of 2012.
Until 31 December 2010, TwoPac was reported as an associated company. As a result of the financing arrangement described above, BioGaia has gained a controlling influence over TwoPac, which is thus consolidated in the BioGaia Group as of January 2011. No additional consideration has been paid for the associated company. The fair value of the shares has been determined as the existing historical cost and no surplus values have been identified. This means that no revaluation effects have arisen.
For comparative information showing how the Group results would have been affected if TwoPac had been consolidated in the Group during 2010, see page 8.
The number of employees in the Group at 30 September 2011 was 63 (45), of which the number of employees in TwoPac was 13.
The business model previously used in Japan was found to be unsuccessful and the company has changed to the business model that is used successfully in other markets. The Japanese subsidiary's sales have now picked up and are expected to increase continuously.
On the balance sheet date, assets in the Japanese subsidiary were reported at SEK 8.6 million in the Group. BioGaia's assessment is that there is no indication of impairment of these assets.
The shares in the subsidiary CapAble amount to a total of SEK 6.9 million in the Parent Company. So far CapAble has reported a loss. CapAble, which is 90.1% owned by BioGaia AB, was started in November 2008 to manufacture and sell the patented LifeTop Cap. BioGaia made total conditional shareholder contributions of SEK 6 million to CapAble in 2009 and 2010. BioGaia's assessment is that CapAble will show good profitability, for which reason there was no indication of impairment on the balance sheet date.
For further information see the administration report and Notes 29 and 30 of the annual report for 2010.
The consolidated financial statements are presented in compliance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and the interpretations published by the IFRS Interpretations Committee (IFRIC) that have been endorsed by the European Commission for application in the EU.
This interim report has been prepared for the Group in accordance with IAS 34, Interim Financial Reporting, and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.
Unless otherwise stated below, the Group and Parent Company have applied the same accounting and valuation standards as in the latest annual report.
The following new standards and interpretations are effective as of 1 January 2011:
The changed IFRS standards and IFRIC interpretations have not had any significant impact on the Group's profit, financial position or disclosures.
Standards and interpretations that are not yet effective and are awaiting approval from the EU have not been evaluated by BioGaia.
BioGaia's goal is to create strong value growth and a good return for the shareholders. This will be achieved through a greater emphasis on the BioGaia brand, increased sales to both existing and new customers and a controlled cost level.
The financial target is a sustainable operating margin (operating profit in relation to sales) of at least 30% with continued strong growth and increased investments in research, product development and brand building.
BioGaia's ambition is to pay a shareholder dividend equal to 30% of profit after tax.
Product launches are planned in a number of countries over the next 12-18 months. In view of the Company's strong portfolio consisting of an increased number of innovative products partly under the company's own brand, together with successful clinical trials and a growing distribution network covering a large share of the key markets, BioGaia's future outlook is bright.
| (Amounts in SEK 000s) | Jan-Sept | Jan-Sept | July-Sept | July-Sept | Jan-Dec | Oct 2010- |
|---|---|---|---|---|---|---|
| 2011 | 2010 | 2011 | 2010 | 2010 | Sept 2011 | |
| Net sales | 232,596 | 173,276 | 73,107 | 48,856 | 236,033 | 295,353 |
| Cost of goods sold | -73,567 | -57,740 | -25,286 | -16,711 | -77,150 | -92,977 |
| Gross profit | 159,029 | 115,536 | 47,821 | 32,145 | 158,883 | 202,376 |
| Selling expenses | -47,791 | -44,950 | -15,532 | -14,167 | -61,336 | -64,177 |
| Administrative expenses | -8,849 | -6,841 | -2,635 | -1,819 | -9,849 | -11,857 |
| Research and development expenses | -24,444 | -22,071 | -7,498 | -6,935 | -29,386 | -31,759 |
| Other operating income/expenses | 1,456 | -2,696 | -49 | -815 | -3,242 | 910 |
| Share in profit/loss of associated company | - | 1,100 | - | 215 | 1,200 | 100 |
| Operating profit | 79,401 | 40,078 | 22,107 | 8,624 | 56,270 | 95,593 |
| Financial income 1) | 2,149 | 11,060 | 845 | 4,320 | 13,517 | 4,606 |
| Financial expenses 2) | -2,311 | -85 | -1,542 | -40 | -100 | -2,326 |
| Profit before tax | 79,239 | 51,053 | 21,410 | 12,904 | 69,687 | 97,873 |
| Tax expense | -21,476 | -16,772 | -5,826 | -4,905 | -22,519 | -27,223 |
| PROFIT FOR THE PERIOD | 57,763 | 34,281 | 15,584 | 7,999 | 47,168 | 70,650 |
| Other comprehensive income Gains/losses arising on translation of the financial |
||||||
| statements of foreign operations | 680 | -132 | 995 | -544 | -15 | 797 |
| Comprehensive income for the period | 58,443 | 34,149 | 16,579 | 7,455 | 47,153 | 71,447 |
| Profit for the period attributable to: | ||||||
| Owners of the Parent Company | 55,956 | 34,427 | 14,846 | 8,043 | 47,250 | 68,779 |
| Non-controlling interests | 1,807 | -146 | 738 | -44 | -82 | 1,871 |
| 57,763 | 34,281 | 15,584 | 7,999 | 47,168 | 70,650 | |
| Comprehensive income for the period attributable to: | ||||||
| Owners of the Parent Company | 56,636 | 34,295 | 15,841 | 7,499 | 47,235 | 69,576 |
| Non-controlling interests | 1,807 | -146 | 738 | -44 | -82 | 1,871 |
| 58,443 | 34,149 | 16,579 | 7,455 | 47,153 | 71,447 | |
| Earnings per share | ||||||
| Basic earnings per share (average number of shares), SEK | 3.24 | 1.99 | 0.86 | 0.46 | 2.74 | 3.98 |
| Diluted earnings per share, SEK | 3.24 | 1.99 | 0.86 | 0.46 | 2.74 | 3.98 |
| Number of shares, thousands | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 |
| Average number of shares, thousands | 17,271 | 17,216 | 17,271 | 17,231 | 17,230 | 17,271 |
| Number of outstanding warrants, thousands | - | - | - | - | - | - |
| Number of outstanding warrants with a dilutive effect, | ||||||
| thousands | - | - | - | - | - | - |
| Number of shares after dilution, thousands | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 |
| 1) Financial income consists of: | ||||||
| Interest income | 2,149 | 565 | 845 | 390 | 1,091 | |
| Exchange gains on forward exchange contracts | - | 10,495 | - | 3,930 | 12,426 | |
| 2,149 | 11,060 | 845 | 4,320 | 13,517 | ||
| 2) Financial expenses consist of: | ||||||
| Exchange losses on forward exchange contracts | -2,249 | - | -1,535 | - | - | |
| Other financial expenses | -62 | -85 | -7 | -40 | 100 | |
| -2,311 | -85 | -1,542 | -40 | 100 |
| CONSOLIDATED BALANCE SHEETS | 30 Sept | 31 Dec | 30 Sept |
|---|---|---|---|
| (Amounts in SEK 000s) | 2011 | 2010 | 2010 |
| ASSETS | |||
| Intangible assets | 453 | 1,173 | 1,413 |
| Tangible assets | 19,941 | 4,216 | 4,550 |
| Shares in associated company | - | 10,641 | 10,541 |
| Non-current receivables from associated company | - | 4,400 | 4,400 |
| Other non-current receivables | 18 | 18 | 18 |
| Total non-current assets | 20,412 | 20,448 | 20,922 |
| Current assets excl. cash and cash equivalents | 70,400 | 60,471 | 65,308 |
| Cash and cash equivalents | 161,434 | 146,903 | 125,713 |
| Total current assets | 231,834 | 207,374 | 191,021 |
| TOTAL ASSETS | 252,246 | 227,822 | 211,943 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to owners of the Parent Company | 209,320 | 187,225 | 174,632 |
| Non-controlling interests | -756 | 98 | -313 |
| Total equity | 208,564 | 187,323 | 174,319 |
| Interest-free current liabilities | 43,682 | 40,499 | 37,624 |
| TOTAL EQUITY AND LIABILITIES | 252,246 | 227,822 | 211,943 |
| Pledged assets | 5,814 | 2,000 | 2,000 |
|---|---|---|---|
| CONSOLIDATED CASH FLOW STATEMENTS |
Jan-Sept | Jan-Sept | July-Sept | July-Sept | Jan-Dec |
|---|---|---|---|---|---|
| (Amounts in SEK 000s) | 2011 | 2010 | 2011 | 2010 | 2010 |
| Operating activities | |||||
| Operating profit | 79,401 | 40,078 | 22,107 | 8,624 | 56,270 |
| Depreciation/amortisation | 5,677 | 2,051 | 1,211 | 561 | 2,836 |
| Share in profit/loss of associated company | - | -1,100 | - | -215 | -1,200 |
| Other non-cash items | -90 | 394 | -19 | 93 | 986 |
| 84,988 | 41,423 | 23,299 | 9,063 | 58,892 | |
| Gains/losses on realised forward exchange contracts | -20 | - | -330 | - | 6,144 |
| Paid tax | -30,121 | - | -5,649 | - | - |
| Interest received and paid | 2,226 | 483 | 977 | 349 | 995 |
| Cash flow from operating activities before changes in working capital |
57,073 | 41,906 | 18,297 | 9,412 | 66,031 |
| Changes in working capital | 129 | 5,090 | 20,516 | 2,490 | 2,934 |
| Cash flow from operating activities | 57,202 | 46,996 | 38,813 | 11,902 | 68,965 |
| Cash flow from investing activities | -8,447 | -314 | -4,396 | -6 | -522 |
| Cash flow from financing activities | -34,542 | -20,948 | 0 | 4,633 | -20,948 |
| Cash flow for the period | 14,213 | 25,734 | 34,417 | 16,529 | 47,495 |
| Cash and cash equivalents at beginning of period | 146,903 | 100,327 | 126,646 | 109,422 | 100,327 |
| Exchange difference in cash and cash equivalents | 318 | -348 | 371 | -238 | -919 |
| Cash and cash equivalents at end of period | 161,434 | 125,713 | 161,434 | 125,713 | 146,903 |
In 2010 TwoPac was reported as an associated company in the BioGaia Group. As of 1 January 2011, TwoPac is reported as a group company (subsidiary). If TwoPac had been consolidated in 2010, the figures for that year would gave been affected as follows.
| Jan-Sept | Jan-Sept | July-Sept | July-Sept | |
|---|---|---|---|---|
| 2010 1) | 2010 2) | 2010 1) | 2010 2) | |
| Net sales | 173,276 | 173,276 | 48,856 | 48,856 |
| Gross profit | 119,917 | 115,536 | 33,222 | 32,145 |
| Operating profit | 41,178 | 40,078 | 8,790 | 8,624 |
| Profit for the period before tax | 52,153 | 51,053 | 13,120 | 12,904 |
| Profit for the period | 35,381 | 34,281 | 8,215 | 7,999 |
| Profit for the period attributable to owners of the Parent Company | 34,427 | 34,427 | 8,043 | 8,043 |
| Basic earnings per share | 1.99 | 1.99 | 0.46 | 0.46 |
| Operating margin | 24% | 23% | 18% | 18% |
| Profit margin | 30% | 29% | 27% | 26% |
| Number of employees | 55 | 45 | 55 | 45 |
| Balance sheet items on the balance sheet date, 30 September 2010: | ||||
| Property, plant and equipment | 14,007 | 4,550 | ||
| Balance sheet total Equity Equity attributable to owners of the Parent Company |
210,260 171,555 174,632 |
211,943 174,319 174,632 |
1) If TwoPac had been reported as a group company in 2010.
2) Corresponds to the comparative figures above, i.e. TwoPac is reported as an associated company.
| (Amounts in SEK 000s) | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| At beginning of period | 187,323 | 161,118 | 161,118 |
| New share issue in BioGaia (warrant programme) | - | 4,863 | 4,863 |
| Dividends | -34,542 | -25,811 | -25,811 |
| Change in group structure | -2,660 | - | - |
| Comprehensive income for the period | 58,443 | 34,149 | 47,153 |
| At end of period | 208,564 | 174,319 | 187,323 |
(Amounts in SEK 000s)
| Jan-Sept | Jan-Sept | July-Sept | July-Sept | Jan-Dec | |
|---|---|---|---|---|---|
| Revenue by segment | 2011 | 2010 | 2011 | 2010 | 2010 |
| Finished consumer products | 157,956 | 120,970 | 46,496 | 31,095 | 165,590 |
| Component products | 73,186 | 50,820 | 25,874 | 17,346 | 68,559 |
| Other products | 1,454 | 1,486 | 737 | 415 | 1,884 |
| 232,596 | 173,276 | 73,107 | 48,856 | 236,033 | |
| Jan-Sept | Jan-Sept | July-Sept | July-Sept | Jan-Dec | |
| Gross profit by segment | 2011 | 2010 | 2011 | 2010 | 2010 |
| Finished consumer products | 111,090 | 79,633 | 33,377 | 19,612 | 109,476 |
| Component products | 46,558 | 34,566 | 13,768 | 12,146 | 47,680 |
| Other products | 1,381 | 1,337 | 676 | 387 | 1,727 |
| 159,029 | 115,536 | 47,821 | 32,145 | 158,883 |
| Group | |||||
|---|---|---|---|---|---|
| Jan-Sept | Jan-Sept | July-Sept | July-Sept | Jan-Dec | |
| Net sales | 2011 | 2010 | 2011 | 2010 | 2010 |
| Europe | 173,777 | 131,082 | 51,473 | 35,785 | 183,858 |
| USA and Canada | 9,288 | 11,664 | 4,922 | 2,868 | 13,879 |
| Asia | 29,526 | 15,155 | 9,104 | 5,430 | 19,564 |
| Rest of world | 20,005 | 15,375 | 7,608 | 4,773 | 18,732 |
| 232,596 | 173,276 | 73,107 | 48,856 | 236,033 |
| PARENT COMPANY INCOME STATEMENTS | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| (Amounts in SEK 000s) | 2011 | 2010 | 2010 |
| Net sales | 225,590 | 173,323 | 233,988 |
| Cost of goods sold | -78,171 | -57,749 | -76,698 |
| Gross profit | 147,419 | 115,574 | 157,290 |
| Selling expenses | -35,464 | -31,491 | -42,355 |
| Administrative expenses | -7,749 | -6,778 | -9,743 |
| Research and development expenses | -24,425 | -22,207 | -29,497 |
| Other operating income/expenses | 1,456 | -2,696 | -3,242 |
| Operating profit | 81,237 | 52,402 | 72,453 |
| Share in profit/loss of associated company | - | 1,100 | 1,200 |
| Impairment loss on receivable from subsidiary | -7,461 | -13,342 | -16,928 |
| Net financial items | 1,851 | 11,802 | 14,665 |
| Profit before tax | 75,627 | 51,962 | 71,390 |
| Tax expense | -21,476 | -15,722 | -23,038 |
| PROFIT FOR THE PERIOD | 54,151 | 36,240 | 48,352 |
| PARENT COMPANY BALANCE SHEETS | 30 Sept | 31 Dec | 30 Sept |
| 2011 | 2010 | 2010 | |
| ASSETS | |||
| Intangible assets | 453 | 1,173 | 1,413 |
| Property, plant and equipment | 2,313 | 3,034 | 3,293 |
| Shares in group companies | 21,110 | 10,469 | 7,469 |
| Shares in associated company | - | 10,641 | 10,541 |
| Non-current receivables from subsidiaries | 16,513 | 1,022 | 1,022 |
| Non-current receivables from associated company | - | 4,400 | 4,400 |
| Total non-current assets | 40,389 | 30,739 | 28,138 |
| Current assets excl. cash and cash equivalents | 61,831 | 56,430 | 62,642 |
| Cash and cash equivalents | 149,354 | 140,840 | 122,383 |
| Total current assets | 211,185 | 197,270 | 185,025 |
| TOTAL ASSETS | 251,574 | 228,009 | 213,163 |
| EQUITY AND LIABILITIES | |||
| Equity | 196,241 | 176,632 | 168,985 |
| Interest-free current liabilities | 55,333 | 51,377 | 44,178 |
| TOTAL EQUITY AND LIABILITIES | 251,574 | 228,009 | 213,163 |
| Pledged assets | 2,000 | 2,000 | 2,000 |
| PARENT COMPANY CASH FLOW STATEMENTS | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| Operating activities | |||
| Operating profit | 81,237 | 52,402 | 72,453 |
| Depreciation/amortisation | 1,627 | 1,811 | 2,369 |
| Other non-cash items | -93 | 374 | 968 |
| Gain/losses on realised foreign exchange contracts | -20 | - | 6,144 |
| Paid tax | -30,121 | - | - |
| Interest received and paid | 2,224 | 484 | 988 |
| Cash flow from operating activities before changes in working capital | 54,854 | 55,071 | 82,922 |
| Changes in working capital | 2,953 | 3,788 | 1,231 |
| Cash flow from operating activities | 57,807 | 58,859 | 84,153 |
| Cash flow from investing activities | -14,844 | -11,555 | -17,780 |
| Cash flow from financing activities | -34,542 | -20,948 | -20,948 |
| Cash flow for the period | 8,421 | 26,356 | 45,425 |
| Cash and cash equivalents at beginning of period | 140,840 | 96,379 | 96,379 |
| Exchange difference in cash and cash equivalents | 93 | -352 | -964 |
| Cash and cash equivalents at end of period | 149,354 | 122,383 | 140,840 |
| (Amounts in SEK 000s) | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| At beginning of year | 176,632 | 153,693 | 153,693 |
| New share issue (warrant programme) | - | 4,863 | 4,863 |
| Dividends | -34,542 | -25,811 | -25,811 |
| Group contributions | - | - | -4,465 |
| Profit for the period | 54,151 | 36,240 | 48,352 |
| At end of period | 196,241 | 168,985 | 176,632 |
(Amounts in SEK 000s)
Annwall & Rothschild Investment AB holds 740,668 class A shares and 1,259,332 class B shares, corresponding to 11.6% of the share capital and 36.2% of the votes. Annwall & Rothschild Investment AB is owned by Peter Rothschild, President of BioGaia AB, and Jan Annwall, a member of the Board of the Parent Company.
The Parent Company holds 100% of the shares in BioGaia Biologics Inc., USA, BioGaia Japan Inc. and Tripac AB.
The Parent Company holds 90.1% of the shares in CapAble AB.
The Parent Company and the Group hold 50% of the shares in TwoPac AB, which is reported as a group company as of 1 January 2011 (previously as an associated company).
| The following transactions have taken place with BioGaia Japan | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| Interest income | 1,650 | 804 | 1,224 |
| Loan provided | 3,567 | 11,174 | 14,339 |
| Sale of goods | 2,244 | 1,364 | 1,364 |
Due to uncertainty about whether the receivable from BioGaia Japan will be recovered in the foreseeable future, a provision has been made for this amount.
| Jan-Sept | Jan-Sept | Jan-Dec | |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| Interest income | 332 | 82 | 119 |
| Loan provided | -11,091 | - | - |
| Purchase of goods | -17,173 | -12,480 | -15,974 |
| The closing balance at the end of the period was as follows: | 30 Sept | 30 Sept | 31 Dec |
| 2011 | 2010 | 2010 | |
| Non-current receivables from TwoPac AB (incl. subsidiary) | 15,491 | 4,400 | 4,400 |
| Current transactions with related parties | |||
| Current receivables from TwoPac AB | 48 | 31 | 37 |
| Current liabilities to TwoPac AB | -3,438 | -1,081 | -1,066 |
| -3,390 | -1,050 | -1,029 |
No significant transactions have taken place with other closely affiliated companies.
| CONSOLIDATED KEY RATIOS 1) | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2011 | 2010 | 2010 | |
| Return on | |||
| - average equity, % | 28% | 20% | 27% |
| - average capital employed, % | 41% | 30% | 40% |
| Capital employed, SEK 000s | 208,564 | 174,319 | 187,323 |
| Number of shares, thousands | 17,271 | 17,271 | 17,271 |
| Average number of shares, thousands | 17,271 | 17,216 | 17,230 |
| Number of outstanding warrants, thousands | - | - | - |
| Average number of outstanding warrants with | |||
| a dilutive effect, thousands | - | - | - |
| Number of shares after dilution | 17,271 | 17,271 | 17,271 |
| Basic earnings per share, SEK | 3.24 | 1.99 | 2.74 |
| Diluted earnings per share, SEK | 3.24 | 1.99 | 2.74 |
| Basic equity per share, SEK | 12.12 | 10.11 | 10.84 |
| Diluted equity per share, SEK | 12.12 | 10.11 | 10.84 |
| Equity/assets ratio | 83% | 82% | 82% |
| Operating margin, % | 34% | 23% | 24% |
| Profit margin, % | 34% | 29% | 30% |
| Average number of employees | 61 | 45 | 45 |
1) The definitions of key ratios correspond to those in the annual report.
| 10 February 2012 | Year-end report 2011 |
|---|---|
| 8 May 2012 | Interim report 1 January – 31 March 2012 |
| 8 May 2012 | Annual General Meeting at 4:00 pm in Stockholm. |
| Shareholders who wish to have a matter dealt with at the AGM must submit a request by 26 March | |
| 2012 to the Board Chairman, BioGaia AB, Box 3242, SE-103 64 STOCKHOLM, Sweden, or by e | |
| mail to [email protected]. | |
| 21 August | Interim report 1 January – 30 June 2012 |
| 23 October | Interim report 1 January – 30 September 2012 |
This interim report provides a true and fair picture of the business activities, financial position and results of operations of the Parent Company and the Group, and describes the significant risks and uncertainties to which the Parent Company and the Group companies are exposed.
Stockholm, 25 October 2011
David Dangoor Jan Annwall Stefan Elving Board Chairman Board member Board member
Thomas Flinck Inger Holmström Jörgen Thorball
Board member Board member Board member
Board member President
Paula Zeilon Peter Rothschild
This interim report has not been examined by the Company's independent auditors.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has healthenhancing effects. BioGaia has also developed unique delivery systems, such as probiotic-containing straws and caps, that make it possible to create probiotic products with a long shelf life.
BioGaia has 63 employees, of whom 20 are based in Stockholm, 21 in Lund, 13 in Eslöv, 2 in Raleigh, USA, 5 in Hiroshima, Japan, and 2 in Shanghai, China.
The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of NASDAQ OMX Nordic Exchange Stockholm.
BioGaia's net sales consist mainly of revenue from the sale of finished consumer products (tablets, drops, Oral Rehydration solution (ORS) and oral health products) to distributors, but also of revenue from the sale of component products such as Reuteri cultures, straws and caps.
BioGaia's products are sold through nutrition, food, natural health and pharmaceutical companies in some 60 countries worldwide.
In Sweden, BioGaia's products are sold under the brands Semper Magdroppar and Vätskeersättning and Gum PerioBalance lozenges in the Apoteket pharmacy chain, as well as Semper whole grain infant cereal and infant formula with active culture and Probiomax gut health tablets in grocery stores.
BioGaia holds patents for the use of Reuteri and certain delivery systems in all major markets.
BioGaia's licensees add Reuteri culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.
Some of BioGaia's distributors sell finished consumer products under their own brand names. For these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.
At the beginning of 2006 BioGaia launched its own consumer brand and today there are distributors that sell BioGaia's finished products under the BioGaia brand in a large number of markets. One central part of BioGaia's strategy is to increase the share of sales consisting of BioGaia-branded products.
Lactobacillus reuteri is one of the world's most well researched probiotics, especially in young children. To date, 80 clinical studies using BioGaia's human strains of Lactobacillus reuteri have been performed on more than 5,000 individuals of all ages. The results have been published in 46 articles in scientific journals.
Studies have been performed on:
Publication of clinical trial results is a key success factor for BioGaia. The International Committee of Medical Journal Editors has initiated a policy requiring clinical investigators to deposit information about trial design into an accepted clinical trials registry before the onset of patient enrolment, and this has now become a prerequisite for publication of trial outcomes in major medical journals. ClinicalTrials.gov is a registry of clinical trials provided by the U.S. National Institutes of Health and BioGaia encourages all clinicians working with BioGaia products to register their trials on this site. Many of the trials are registered at an early stage, which means that some of the registered trials will not be performed as planned. Consequently, BioGaia takes no responsibility for ensuring that the registered trials reach completion or are successfully reported in the register or the scientific literature. When clinical trials results do become available, BioGaia will report these through press releases.
2011-10-17 BioGaia signs new exclusive distribution agreement with Victus
2011-09-21 BioGaia signs agreement with the largest pharmaceutical company in the Philippines for its probiotic chewable tablets 2011-08-18 BioGaia signs exclusive agreement with Fleet Laboratories in the USA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.